Adial Pharmaceuticals Inc represents a commitment to improving patient treatment outcomes by focusing on the development of innovative therapies. The company is dedicated to advancing precision medicine through personalized treatment options. Adial Pharmaceuticals Inc values research, collaboration, and patient-centric care, aiming to address unmet medical needs with its cutting-edge solutions. By leveraging advanced technologies and strategic partnerships, the company aims to create value for patients, healthcare providers, and shareholders. Adial Pharmaceuticals Inc's corporate philosophy revolves around the pursuit of scientific excellence, ethical practices, and delivering innovative solutions to improve the quality of life for individuals affected by various medical conditions.

Adial Pharmaceuticals Inc is primarily present in the United States of America.

Some significant milestones achieved by Adial Pharmaceuticals Inc include the successful completion of Phase 2b clinical trials for their lead product, AD04, which aims to treat alcohol use disorder. The company has also obtained Fast Track Designation from the U.S. FDA for AD04, recognizing the urgent need for effective treatments in this area. Adial Pharmaceuticals has strengthened its intellectual property portfolio with the issuance of multiple patents and has secured collaborations with leading research institutions to further develop their innovative therapeutic solutions. These milestones highlight the company's progress in advancing its novel drug candidates and signify promising prospects for Adial Pharmaceuticals Inc.

Adial Pharmaceuticals Inc is a biopharmaceutical company based in Virginia, USA. It was founded in 2010 and is focused on developing innovative treatments for addiction and related disorders. Adial Pharmaceuticals aims to revolutionize the way addiction is treated by providing personalized medications and therapeutic interventions. The company's flagship product, AD04, is being developed as a potential treatment for Alcohol Use Disorder (AUD). Adial Pharmaceuticals is committed to improving the lives of individuals affected by addiction and aims to address the growing need for effective and accessible treatment options. With its dedicated team and visionary approach, Adial Pharmaceuticals continues to make significant strides in the field of addiction therapeutics.

Some of the main competitors of Adial Pharmaceuticals Inc in the market include Alkermes plc, BioMarin Pharmaceutical Inc, and Catabasis Pharmaceuticals Inc.

Adial Pharmaceuticals Inc primarily operates in the pharmaceutical industry.

Adial Pharmaceuticals Inc. operates with the business model of developing and commercializing innovative biopharmaceutical drugs. The company primarily focuses on the development of treatments for alcohol use disorder (AUD) and other addiction-related disorders. Adial's proprietary technology, known as AD04, is a selective serotonin-3 antagonist, which is being developed for the treatment of AUD. By leveraging its expertise and research capabilities, Adial Pharmaceuticals aims to address the unmet medical needs in the addiction treatment space. With an emphasis on improving patient outcomes and overall quality of life, Adial Pharmaceuticals strives to bring effective and transformative therapies to the market.

KGV Adial Pharmaceuticals iznosi −0,44.

Koeficijent cijene i prometa Adial Pharmaceuticals iznosi 0.

AlleAktien Qualitätsscore za Adial Pharmaceuticals je 1/10.

Prihod trenutno ne može biti izračunat za Adial Pharmaceuticals.

Dobit očekivana Adial Pharmaceuticals iznosi −3,43 mil. USD.

Adial Pharmaceuticals Inc is a leading biotechnology company that develops innovative drugs for the treatment of alcoholism and other diseases. The company focuses on researching, developing, and marketing novel therapies that target the causes of alcoholism. The business operations of Adial Pharmaceuticals Inc are divided into three main divisions: research and development, sales and marketing, and licensing and partnerships. The company's focus is on developing and marketing medications tailored to individual needs. In the research and development segment, the company utilizes its expertise to identify novel therapies that aim to reduce the effects of alcoholism. The company has a pipeline of candidate drugs that are designed to modulate the brain's reward system and reduce alcohol consumption. Research and development activities focusing on alcoholism and other neuropsychiatric disorders are conducted by the company's research and development departments. In the sales and marketing segment, Adial Pharmaceuticals Inc has an experienced team that works closely with physicians and healthcare facilities to raise awareness of its products. The company relies on targeted marketing and advertising efforts to ensure that its products are known and specifically prescribed by medical professionals. In the licensing and partnership sector, Adial Pharmaceuticals Inc pursues a proactive strategy to bring its products to markets worldwide. The company has formed partnerships with reputable pharmaceutical companies to accelerate the distribution of its products in global markets. The company focuses on strengthening its market position by entering into informed partnerships and licensing agreements to expand the reach of its products. The portfolio of Adial Pharmaceuticals Inc includes various products that are used in a comprehensive alcohol therapy. The Nalmefene hydrochloride tablet system for adults with alcohol dependence is the company's first drug approved in Europe. The company has also advanced the development of AD04, a drug for the treatment of alcohol dependence currently in phase III clinical trials. In summary, Adial Pharmaceuticals Inc's mission is to develop innovative therapies for alcoholism and other neuropsychiatric disorders. The company relies on research and development, sales and marketing, and licensing and partnerships to bring its products to markets worldwide. Adial Pharmaceuticals Inc aims to raise awareness of its products to ensure the spread of its products and the success of its mission.

Adial Pharmaceuticals isplaćuje dividendu od 0 USD raspoređenu preko isplata godišnje.

Dividenda za Adial Pharmaceuticals trenutno se ne može izračunati ili tvrtka ne isplaćuje dividendu.

ISIN od Adial Pharmaceuticals je US00688A1060.

WKN od Adial Pharmaceuticals je A2N38J.

Oznaka burze tvrtke Adial Pharmaceuticals je ADIL.

U posljednjih 12 mjeseci Adial Pharmaceuticals je isplatio dividendu u iznosu od . To odgovara prinosu dividende od oko . Za sljedećih 12 mjeseci Adial Pharmaceuticals će vjerojatno isplatiti dividendu u iznosu od 0 USD.

Trenutni prinos dividende od Adial Pharmaceuticals iznosi .

Adial Pharmaceuticals isplaćuje dividende kvartalno. One se isplaćuju u mjesecima .

Adial Pharmaceuticals je isplatio dividendu svake godine u posljednjih 0 godina.

Za nadolazećih 12 mjeseci očekuje se isplata dividendi u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Adial Pharmaceuticals se pripisuje sektoru 'Zdravlje'.

Da bi primili posljednju dividendu od Adial Pharmaceuticals od 18. 07. 2024. u iznosu od 0 USD, trebali ste imati dionicu u portfelju prije Ex-dana 18. 07. 2024..

Posljednja isplata dividende izvršena je 18. 07. 2024..

U godini 2023 su od Adial Pharmaceuticals 0 USD isplaćene kao dividende.

Dividende od Adial Pharmaceuticals isplaćuju se u USD.